E-Z-EM, Inc., Announces Preliminary Results for First Quarter Fiscal 2000

Business Wire, Sept 30, 1999

WESTBURY, N.Y.--(BUSINESS WIRE)--Sept. 30, 1999--

E-Z-EM, Inc., (AMEX EZM.A and EZM.B) today announced anticipated results for the first fiscal quarter ended August 28, 1999. Based on preliminary information, the Company expects to report net earnings of $1,798,000, $.18 per share, on net sales of $27,197,000. In the first quarter of the last fiscal year, the Company reported net earnings of $1,470,000 on net sales of $25,665,000. Basic and diluted earnings were $.15 and $.14 per share respectively. Operating profit in this year's first quarter, the sixth consecutive quarter of profitability for the Company, improved 24% to $2,545,000 from $2,050,000 last year.

E-Z-EM is the world's largest manufacturer of contrast agents for gastrointestinal radiology, and, through its wholly-owned subsidiary AngioDynamics, manufactures three types of medical devices: angiography, therapeutic and coronary. Enteric Products, Inc., reported as part of the Diagnostic segment, develops, manufactures and markets tests for detection of the ulcer-causing bacterium Helicobacter pylori. For additional information, please contact Frank Kerrigon at 1-800-544-4624, ext. 325, or visit our corporate web site at www.ezem.com.

The statements made in this press release contain certain forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ from the Company's expectations. In addition to the matters described in this release, future actions by the FDA, results of pending or future clinical trials, as well as the risk factors listed from time to time in the Company's SEC reports, including but not limited to its Form 10-Q for the quarter ended August 28, 1999, as well as its Annual Report on Form 10-K, may affect the actual results achieved by the Company.